Company intelligence / Profile preview

Injeq

Ownership: Private
Employees: ~19
Development stage: Commercial

Overview

The IQ-Tip smart needle demonstrated improved safety and accuracy for lumbar punctures across age groups, with clinical performance validated by three trials. CE-marked since late 2021. Used to reduce traumatic punctures and post-dural headaches, especially valuable in pediatric leukemia treatment and neurological research. The product was being commercialized across Europe before asset acquisition.

Therapeutic areas: OtherNeurology
Modalities: Device (specifically smart needle systems)
Industry: Surgical Medical Devices

Partnerships

Distribution agreements with partners/distributors across Finland, Germany, Scandinavia, Italy, Austria, France, Slovenia & Switzerland prior to acquisition.

Beyond the preview

Go deeper on Injeq.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Injeq.

Explore the full profile